1679.2000 -3.90 (-0.23%)
NSE Jun 06, 2025 15:31 PM
Volume: 2.5M
 

1679.20
-0.23%
Emkay
contribution of other operational income or other income to the overall numbers. The beat on revenue was driven by a stronger-than-expected India business (revenue of Rs21.5bn was higher by ~8% v/s estimates) as well as US geography (standalone revenue of US$225mn, which reflects a growth of 17% qoq). Q1FY19 clearly benefitted from the launch of AG of gWelchol, plus the impact of supplies normalizing from Halol. However, SUNP remains emphatic that qoq growth was a factor of both and therefore there is no channel filling on account of Halol normalizing. In other words, it means that the...
Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings
More from Sun Pharmaceutical Industries Ltd.
Recommended